When treating blood pressure, guidelines recommend that clinicians aim to achieve a target level. 1 However, guidelines give only limited guidance on how many drugs patients may need to take to achieve these target levels. This paper models the effects of treatments in hypertensive patients to produce an estimate of the number of medications hypertensive patients aged 35-74 years might be expected to need to achieve a target systolic blood pressure of under 140 mmHg and a target diastolic blood pressure of under 90 mmHg.
Recent meta-analysis has produced robust estimates of the effects of treatment on blood pressure. 2 At standard dose an antihypertensive reduces blood pressure by 9.1/5.5 mmHg in a patient whose blood pressure is 154/97 mmHg; at twice standard dose the effect is 10.9/6.5 mmHg. (See www.smd.qmul.ac.uk/wolfson/bpchol for standard doses of all drugs, eg bendroflumethazide 2.5 mg, atenolol 50 mg.) The effect is proportionately larger in patients with higher blood pressures and proportionately smaller in those with lower. This provides an estimate of the likely effects of treatment on patients. Combined with data on the prevalence of hypertension and the pretreatment blood pressures of hypertensives, it can be used to obtain the best estimate of the number of drugs required to achieve target levels in a typical cohort of patients.
Data from the Health Survey for England of 1998, 1999 and 2000 were combined, providing a data set of 13 284 persons with complete cardiovascular risk factor information. 3 Of these, 8173 are aged 35-74 years. Individual 10-year coronary risks were calculated for each of these persons using the Framingham risk equation. 4 Patients are eligible for treatment if their true blood pressure and true coronary risk exceed treatment thresholds based on current British guidelines. These are either blood pressure over 160/100 mmHg (diastolic or systolic), or blood pressure over 140/90 mmHg with 10-year coronary risk exceeding 15%. 1 In addition, patients are eligible for further treatment if their blood pressure exceeds 140/90 mmHg and are already on antihypertensive treatment.
For each subject eligible, the effects on systolic and diastolic blood pressures of a single antihypertensive drug at standard dose were calculated using the following formulae, derived from Law et al's meta-analysis:
The blood pressure effects of further drugs at standard dose are additive, whereas increasing the dose of the drug has only a small effect on blood pressure.
2 Addition of further drugs is therefore more likely to achieve target blood pressures than increasing the dose of existing drugs. From this was calculated the number of drugs required to achieve target blood pressure. Patients already on antihypertensive treatment were assumed to be already taking one drug. In a sensitivity analysis, the effect of assuming drugs are used at twice standard dose is also calculated.
Using the specified definition, there are a total of 1963 hypertensive patients in the age group 35-74 years. The prevalence of hypertension in men aged 35-74 years is 29.9% (1138 of 3804) and in women is 18.9% (825 of 4369). It is estimated that in 85.3% (1675) of hypertensives aged 35-74 years, more drugs are needed to achieve the systolic than the diastolic blood pressure target; in 5.7% (112) more drugs are needed to achieve the diastolic than the systolic blood pressure target; in 9.0% (176) both targets are achieved with the same number of drugs.
In this model, 53.9% of hypertensive men aged 35-74 years and 50.2% of women require two or three drugs to achieve target blood pressure. A significant minority of men (22.9%) and women (34.8%) will require four or more antihypertensive drugs. Some patients will require as many as seven. Hypertensive patients under 35 years require at least three drugs to achieve target levels. This is because their pretreatment blood pressure must exceed 160/ 100 mmHg to be eligible for treatment. Patients over 75 years of age also tend to require more drugs than younger patients (Table 1) .
When the analysis is repeated with drugs given at twice standard dose 60.3% of hypertensive men aged 35-74 years and 61.9% of women require two or three drugs to achieve target blood pressure. At twice standard dose, 11.5% of men and 20.2% of women require four or more antihypertensive drugs.
Since patients on treatment are assumed to be already receiving only one drug, this analysis may underestimate the number of drugs patients will need. The model does not account for individual variation in patients' responses to treatment: younger, white patients respond better to drugs acting on the renin-angiotensin system and older (and black) patients respond better to drugs acting through other mechanisms. Combinations of drugs acting through different mechanisms have greater effects than combinations acting through the same mechanisms. However, since most patients require many drugs to achieve target blood pressures, most patients will require drugs acting through both mechanisms. It is not clear whether patients will always judge the incremental benefits of multiple drug treatment to be worthwhile. Young hypertensives are not at high risk of cardiovascular disease; therefore, the incremental benefits are very small. In old hypertensives, the disadvantages and adverse effects of polypharmacy may be greater; therefore, the incremental hazards may be significant. Nor is it clear that the incremental benefits are worth the costs to the health service. Attempts to persuade clinicians to achieve a blood pressure target may therefore conflict both with patients' preferences and rational use of health service resources. A more rational approach to cardiovascular disease prevention would explicitly consider the 
